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Abstract
Background: We previously identified an association between a mismatch repair gene, MLH1, promoter SNP (rs1800734)
and microsatellite unstable (MSI-H) colorectal cancers (CRCs) in two samples. The current study expanded on this finding as
we explored the genetic basis of DNA methylation in this region of chromosome 3. We hypothesized that specific
polymorphisms in the MLH1 gene region predispose it to DNA methylation, resulting in the loss of MLH1 gene expression,
mismatch-repair function, and consequently to genome-wide microsatellite instability.
Methodology/Principal Findings: We first tested our hypothesis in one sample from Ontario (901 cases, 1,097 controls) and
replicated major findings in two additional samples from Newfoundland and Labrador (479 cases, 336 controls) and from
Seattle (591 cases, 629 controls). Logistic regression was used to test for association between SNPs in the region of MLH1
and CRC, MSI-H CRC, MLH1 gene expression in CRC, and DNA methylation in CRC. The association between rs1800734 and
MSI-H CRCs, previously reported in Ontario and Newfoundland, was replicated in the Seattle sample. Two additional SNPs, in
strong linkage disequilibrium with rs1800734, showed strong associations with MLH1 promoter methylation, loss of MLH1
protein, and MSI-H CRC in all three samples. The logistic regression model of MSI-H CRC that included MLH1-promoter-
methylation status and MLH1 immunohisotchemistry status fit most parsimoniously in all three samples combined. When
rs1800734 was added to this model, its effect was not statistically significant (P-value =0.72 vs. 2.3610
24 when the SNP was
examined alone).
Conclusions/Significance: The observed association of rs1800734 with MSI-H CRC occurs through its effect on the MLH1
promoter methylation, MLH1 IHC deficiency, or both.
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Colorectal cancer (CRC) is the fourth most common cancer,
and second leading cause of cancer-related deaths in North
America [1]. CRCs can be parsimoniously subdivided into two
major groups defined by the genetic pathways involved. The
suppressor pathway, observed in .80% of CRC cases, involves
abnormalities of the APC/wingless signalling pathway and is
characterized by frequent somatic mutations of oncogenes and loss
of heterozygosity of tumor suppressor genes, chromosomal
instability, and microsatellite stable (MSS) tumors. The mutator
pathway, on the other hand, accounts for ,15–20% of CRC cases
and results from a deficiency of the mismatch-repair (MMR)
system, which leads to genome-wide microsatellite instability (MSI)
[2,3]. MSI tumors have clinicopathologic features distinct from
MSS tumors in that they tend to occur more commonly in
proximal colon, have mucinous histology, tumor infiltrating
lymphocytes, poor differentiation, and Crohn’s-like reaction [4].
CRCs can also be classified based on epigenetic instability into
CpG Island Methylator Phenotype (CIMP)-positive and CIMP-
negative tumors [5]. CIMP-positive CRC tumors can be
subsequently subdivided into two groups, a more common CIMP1
tumors, which are MSI-H due to MLH1 promoter methylation,
and CIMP2 tumors, which are MSS [5]. Approximately 80–90%
of sporadic MSI CRCs exhibit loss of MMR function due to
MLH1 promoter methylation [6,7]. The potential mechanism by
which MLH1 is epigenetically silenced is unclear.
Our previous work aimed to elucidate the role of a panel of
SNPs in MMR genes in CRC. Included in this panel was the
MLH1-93G.A promoter polymorphism (rs1800734), and we
observed its association with MSI-H tumors in two samples from
the Canadian provinces of Ontario and Newfoundland and
Labrador [8]. Several studies subsequently confirmed and
expanded on our findings and have observed associations between
the MLH1-93G.A polymorphism and MLH1 promoter methyl-
ation in CIMP CRCs, as well as MLH1 IHC deficiency [9,10,11].
However, no predictive model has been proposed to describe such
findings. The association between the MLH1 promoter polymor-
phism (rs1800734) and methylation may indicate sequence
specificity to DNA methylation.
We hypothesized a stepwise progression to MSI-H CRCs based
on genetic susceptibility to DNA methylation leading to MLH1
gene silencing and microsatellite instability (Figure 1). Further,
we hypothesized that the MLH1-93G.A polymorphism may be in
strong linkage disequilibrium (LD) with other variants, and that
one or more of these variants predispose the region to methylation,
which then results in loss of MLH1 gene expression and a defective
MMR system, leading to microsatellite instability. We have
undertaken a population-based approach using three independent
samples. This study used a unique combination of genetic
epidemiology and functional strategies to identify and characterize
alleles that play a role in modifying CRC development in an
important and common subgroup of cases.
Materials and Methods
SNP Selection Criteria
The polymorphisms analyzed by 59 nuclease assay in this study
were selected on the basis of extensive database and literature
searches as described previously [8,12]. The 500 kb region of
chromosome 3 surrounding MLH1 was genotyped for all available
polymorphisms from a combination of Affymetrix GeneChip
Human Mapping 100K and 500K platforms. In addition, we
selected SNPs in the region of interest that are in strong LD with
rs1800734 in the HapMap data (release 27 in CEU population),
publicly available at http://www.hapmap.org. Two such SNPs
were identified and were also included.
Study Subjects
We conducted this study with subjects from three different
locations: the province of Ontario, the province of Newfoundland
and Labrador (hereafter referred to as Newfoundland), and the
Seattle metropolitan area. In all locations, only individuals with a
single tumor were included. CRC patients and unaffected controls
from Ontario and Newfoundland were accrued as described
previously [8,12]. Briefly, for Ontario 1004 CRC patients and
1957 controls were identified by the Ontario Familial Colorectal
Cancer Registry (OFCCR) [13]. In order to minimize the
potential for population stratification we excluded from the
analyses cases who were non-white and those who did not report
ethnicity. Of the 1004 case patients, 929 were white. No related
cases were used in the study. Further, we excluded all CRC
patients with known MMR germline gene mutations (11 cases with
a known mutation in MLH1, 10 in MSH2, and one in MSH6) and
all CRC cases that were deficient in one of the MMR proteins,
other than MLH1 (14 MSH2/MSH6 IHC deficient tumors). 901
CRC patients remained and constitute the Ontario cases. All
patient information as well as blood and tissue specimens were
obtained as described previously [8].
A total of 1957 control subjects from Ontario agreed to
participate in the study and completed all three questionnaires
(family, personal, and diet questionnaires). Of the 1957, 1314
controls provided blood samples, and 1097 of them were white.
These 1097 control subjects were successfully genotyped and thus
constituted the Ontario controls. Approximately 21% of OFCCR
cases and 12% of controls have first-degree relatives affected with
CRC.
The accrual pattern followed by the Newfoundland Familial
Colorectal Cancer Registry (NFCCR) was similar to that followed
by the OFCCR. Patients with CRC were identified through the
Newfoundland tumor registry; 1144 CRC patients were identified,
Figure 1. Proposed model for genetic susceptibility to DNA
methylation in sporadic MSI-H CRCs. Specific SNPs predispose the
region, including the MLH1 gene promoter, to methylation, which
results in promoter silencing and loss of MLH1 gene expression that is
measured by immunohistochemical staining. Loss of the MLH1 gene
expression leads to genome-wide microsatellite instability and MSI-H
colorectal cancer.
doi:10.1371/journal.pone.0013314.g001
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555 provided blood samples; 490 provided ethnicity information
and were classified as white. No related cases were used in the
study. Four CRC cases with known germline mutations in MSH2
were excluded, as were 11 non-MLH1 MMR IHC deficient cases
(5 for MSH2, 5 for MSH6, and 1 for PMS2 deficiency). The
remaining 479 CRC patients constitute the Newfoundland cases.
Newfoundland controls were recruited using random digit
dialing, and matched to cases by sex and 5-year age group; 1602
controls agreed to participate, of whom 336, to this stage, have
completed all three questionnaires and provided blood samples.
No related controls were used in the study. Approximately 31% of
NFCCR cases and 18% of controls had first-degree relatives
affected with CRC.
For Seattle, cases and controls were recruited by the Fred
Hutchinson Cancer Research Center (FHCRC) as described
previously [14]. Briefly, CRC patients who were diagnosed
between the ages of 20 and 74 years in Washington’s King,
Snohomish, or Pierce Counties between January 1998 and June
2002 were contacted. All CRC cases were included regardless of
family history. Of the 1814 cases and 1531 controls who
completed the two questionnaires, 1497 cases and 745 controls
donated a blood sample. For this study, we obtained DNA samples
for 668 CRC cases and 667 controls of Caucasian ethnicity.
Fifteen MMR IHC deficient CRC cases were excluded (10 for
MSH2, 1 for MSH6, and 4 for PMS2 deficiency). No related cases
or controls were used in the study. Approximately 14% of
FHCRC cases and 8% of controls had first-degree relatives
affected with CRC.
Data were collected on age at diagnosis (for cases), age at
completion of the family history questionnaire, tumor location,
tumor stage, and tumor grade, when available, through review of
pathologic and/or surgical reports. Tumors were staged and
graded according to the method of the American Joint Committee
on Cancer [15]. Blood and tissue specimens were obtained upon
informed written consent to participate in the study, as per
protocols approved by the research ethics boards of Mount Sinai
Hospital, University of Toronto, Memorial University of New-
foundland, and Fred Hutchinson Cancer Research Center.
Molecular Genetic Analysis
Single-Nucleotide Polymorphism Genotyping. Peripheral
blood lymphocytes were isolated from whole blood by use of
Ficoll–Paque gradient centrifugation according to the
manufacturer’s protocol (Amersham Biosciences, Baie d’Urfe ´,
Quebec, Canada). Phenol–chloroform or the Qiagen DNA
extraction kit (Qiagen Inc., Montgomery Co., MD) was used to
extract genomic DNA from lymphocytes. The fluorogenic 59
nuclease polymerase chain reaction assay or the TaqMan assay
[16] was used to genotype each of the following five SNPs: MLH1–
93G.A (rs1800734), I219V (rs1799977), IVS14-19A.G
(rs9876116), LRRFIP2 intron 26 IVS26-18T.C (rs749072),
LBA1 intron 8 (rs4431050), and intergenic rs13098279.
Sequences of primers and probes as well as the master reaction
mixtures for rs1800734, rs1799977, and rs9876116 were described
previously [8]. The LRRFIP2 rs749072, LBA1 rs4431050, and
intergenic rs13098279 polymorphisms were genotyped by use of
the Eurogentec qtPCR kit (Eurogentec, San Diego, CA) [8].
Sequences of primers and probes for rs749072, rs13098279, and
rs4431050 are provided in Supplementary File S4.
SNPs located in the 500 kb region of chromosome 3
surrounding the MLH1 gene were genotyped in the Ontario
samples using the Affymetrix GeneChip Human Mapping 100K
and 500K platforms as a part of the Assessment of Risk of
Colorectal Tumors in Canada (ARCTIC) project, described
previously [17]. 94 SNPs in the 500 kb region, in addition to the
5 SNPs genotyped by TaqMan, were genotyped for the Ontario
samples spanning the following genes: DCLK3, LBA1, EP-
M2AIP1, MLH1, LRRFIP2,a n dGOLGA4.T h el i s to fS N P s
genotyped for the Ontario samples is provided in Supplemen-
tary File S1. The Newfoundland and Seattle samples were
genotyped using the Illumina ISelect 500K Chip platform. A
total of 16 SNPs in this region were genotyped including
rs1800734, rs749072, and rs13098279. The Newfoundland
samples were further characterized for three polymorphisms:
rs1799977 and rs9876116 genotyped previously [8], and LBA1
rs4431050. The rs1800734 SNP was genotyped both by the
Affymetrix Chips and Taqman platforms in Ontario and was
used to validate genotyping calls. Out of 1884 samples genotyped
by both methods there were 11 discordant calls (0.58%,
Supplementary File S1).
The quality control for genotyping was performed as described
previously [17]. Briefly, SNPs were excluded from the data
analysis if the minor allele frequency was less than 1% and the call
rate was less than 87% in the controls in each of the three study
centres. Additionally, SNPs were excluded if the P-value from a
test for Hardy-Weinberg equilibrium was less than 10
24 in the
controls. Individuals were excluded if the genotyping call rate was
less than 87%.
Tumor Microsatellite Instability Analysis. Tumor MSI
analysis was performed as described previously [18]. Briefly,
paraffin-embedded colorectal tumor and matched normal colonic
tissue from patients with incident cases of CRC were
microdissected in areas with more than 70% cellularity. PCR on
DNA from CRC tumor and matched normal colonic tissue was
used to establish and compare the MSI patterns. MSI analysis was
carried out with at least five microsatellite markers from the panel
of 10 microsatellite markers, as recommended by the National
Cancer Institute [19]. MSI status was assigned as MSI high (MSI-
H, $30% unstable markers among all markers tested), MSI low
(MSI-L, ,30% markers unstable), or microsatellite stable (MSS,
no unstable markers) as recommended [19]. For the analysis, MSI-
L and MSS groups were combined into one group (hereafter
referred to as ‘‘MSS/L’’). Primers were obtained from Applied
Biosystems (Foster City, CA), and primer sequences were
described previously [8].
MMR Protein Immunohistochemical Staining
Formalin-fixed, paraffin-embedded CRC tissues, collected for
diagnostic purpose, sectioned at 4 mm were deparaffinized and
rehydrated with alcohol and xylene for immunohistochemical
analysis of MLH1 as described previously [20,21]. Following
rehydration, the slides were placed into either a pressure cooker or
microwave antigen retrieval medium (10mmol/L citrate buffer at
pH 6.0 for 3 minutes at 115uC in microMED T/T Mega; Hacker
Instruments & Industries, Inc., Fairfield, NJ). Protein blocker
(20%) with avidin was used to prevent nonspecific binding (Signet
Laboratories, Inc, Dedham, MA). After the slides were washed in
PBS, the sections were incubated with mouse antibody against
MLH1 (1:40; G168-728, PharMingen, San Diego, CA), MSH2
(1:100; FE 11, Oncogene Research Products, Cambridge, MA),
MSH6 (1:100; 44, BD Transduction Laboratories, Mississauga,
Ontario, Canada), or PMS2 (1:50; BD Biosciences PharMingen,
Mississauga, Ontario, Canada) for 1 hour. The antibodies were
then detected using avidin-biotin: 3,39-diaminobenzidine tetra-
chloride was used as the chromogen and hematoxylin for
counterstaining.
SNPs and DNA Methylation
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MLH1 promoter methylation was analyzed using MethyLight
[22,23]. Tumor DNA from the available cases was subject to
sodium bisulfite conversion using EZ DNA Methylation Gold Kit
(Zymo Research, Orange, CA) per manufacturer’s recommenda-
tions.
MethyLight analysis of the MLH1 promoter was performed as
previously described [23]. The Alu-C4 control reaction was used
to normalize for bisulfite-converted input DNA [23]. The samples
were classified as positive for MLH1 promoter methylation if
percent methylated reference (PMR) $10, as described previously
[23]. The primer and probe sequences for the MLH1 and Alu-C4,
as well as the real-time PCR program for MethyLight analysis
have been previously reported [23]. All assays were run in 96-well
polypropylene plates (Axygen Scientific, Union City, CA) and the
results were analyzed using the ABI 7500HT Real-Time PCR
instrument and the accompanying software, SDS version 2.2
(Applied Biosystems, Foster City, CA). Independent quality
control for the MLH1 promoter methylation analysis was
performed externally on 15% of Ontario samples.
Statistical Analysis
Each of the following outcomes was tested for association with
each SNP using logistic regression: colon cancer (all CRC cases
versus controls), methylation (MLH1 methylated tumors versus
non-methylated tumors), IHC (MLH1 IHC-deficient versus
proficient tumors), and MSI (MSI-H versus MSS/L tumors),
using an additive coding of genotypes for each SNP. Sex and age
at exam, collected for patients and unaffected controls, were used
as covariates when CRC was the outcome, whereas sex and age at
diagnosis (available for patients only) were used in models with the
other outcomes. Analysis of separate models for the three
collection sites and the combined dataset was undertaken. In the
analysis of the combined data, site was included as a covariate.
Multiple logistic regression models for MSI status were also
evaluated in the subset of the data in which there were no missing
values for all of the variables included in the models (age, MSI,
IHC, methylation, and three SNPs). MSI status was regressed on
combinations of IHC, methylation and SNP, for each of three
SNPs that showed associations in the initial logistic regression
models. Since the sample sizes are small, particularly in Seattle, the
regression was performed with all samples combined, while using a
covariate for recruitment location. To check for consistency in the
results, the models were also run on each sample separately. Due
to the strong association between MSI, IHC, and methylation and
nearly complete separation, maximum penalized likelihood was
used to produce finite parameter estimates [24]. All statistical
analyses were performed with R 2.7.0 (http://www.R-project.org).
In order to control for the effect of multiple testing, an effective
number of tests was estimated for Ontario, Seattle and
Newfoundland, based on the procedure of Li and Ji [25]. This
procedure uses spectral decomposition of the observed correlation
between SNPs to estimate the number of completely and partially
correlated tests. Thus, to control for type I error, the nominal
significance level of 0.05 is adjusted by the estimated effective
number of tests using the normal Bonferroni procedure. The
spectral decomposition was performed using modified scripts
downloaded from the website of Dale Nyholt (http://gump.qimr.
edu.au/general/daleN/SNPSpD, 4 July 2005), along with GOLD
1.1.0 [26] and R 2.7.0 (http:www.R-project.org).
Results
We genotyped 901 cases and 1097 controls from Ontario for 99
SNPs in a 500 kb region of chromosome 3 surrounding the MLH1
gene (Figure 2).
We removed 25 SNPs due to quality control issues: minor allele
frequency ,1% (22), call rate ,87% (1), or Hardy-Weinberg P-
value ,10
24 (2), resulting in 74 analyzed SNPs. We then screened
the Newfoundland (479 cases and 336 controls) and Seattle (591
cases and 629 controls) samples for 19 and 16 SNPs of interest,
respectively. All markers in the Newfoundland and Seattle samples
passed quality control filters. Tumor microsatellite instability was
evaluated for 744 Ontario, 463 Newfoundland, and 487 Seattle
cases. MLH1 IHC staining was undertaken on 709 Ontario, 462
Newfoundland, and 517 Seattle cases, and MLH1 promoter
methylation analysis was performed on 569 Ontario, 468
Newfoundland, and 210 Seattle cases. Characteristics of all three
sample populations are summarized in Table 1. General clinical
and pathologic features of CRC of our total case populations were
similar to those of case populations used in the multiple logistic
regression models, with the exception of Seattle, where there was a
bias towards MSI-H tumors (and correspondingly IHC-deficient
tumors). The list of all polymorphisms genotyped is provided in
Figure 2. Region of chromosome 3 examined with genes and 3 SNPs. A total of 99 polymorphisms were examined in the Ontario samples
across a 500kb region of chromosome 3 surrounding the MLH1 gene. Genes in this region are outlined (top panel) along with their transcriptional
directionality (bottom panel). The three polymorphisms of interest are indicated. Modified from Ensembl (www.ensembl.org).
doi:10.1371/journal.pone.0013314.g002
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All Subjects Ontario Seattle Newfoundland
Controls No. 1097 629 336
Percent male 56 41 55
Age at exam, y – mean (sd) 64.3 (8.6) 60.6 (10.2) 60.2 (8.6)
Cases No. 901 591 479
Percent male 53 40 62
Age at exam, y – mean (sd) 61.6 (9.0) 60.1 (10.2) 62.3 (9.1)
Age at diagnosis, y – mean (sd) 60.7 (9.0) 60.1 (10.2) 60.9 (8.9)
Tumor Histological Grade No. 719 541 417
1 – Well differentiated – No. (%) 79 (11.0) 46 (8.5) 58 (13.9)
2 – Moderately differentiated – No. (%) 552 (76.8) 374 (69.1) 324 (77.7)
3 – Poorly differentiated – No. (%) 88 (12.2) 121 (22.3) 35 (8.4)
TNM Stage No. 751 499 Na
Stage I – No. (%) 172 (22.9) 150 (30.1) Na
Stage II – No. (%) 291 (38.7) 140 (28.1) Na
Stage III – No. (%) 241 (32.1) 167 (33.5) Na
Stage IV – No. (%) 47 (6.3) 42 (8.4) Na
Tumor MSI status, No. 744 487 463
MSI-high – No. (%) 90 (12.1) 75 (15.4) 40 (8.6)
MSI-low – No. (%) 3 (0.4) 48 (9.9) 23 (5.0)
MSI-stable – No. (%) 651 (87.5) 364 (74.7) 400 (86.4)
MLH1 IHC status, No. 709 517 462
IHC present – No. (%) 635 (89.6) 447 (86.5) 428 (92.6)
IHC deficient – No. (%) 74 (10.4) 70 (13.5) 34 (7.4)
MLH1 promoter methylation status, No. 569 210 468
Methylation positive – No. (%) 62 (10.9) 58 (27.6) 25 (5.3)
Methylation negative – No. (%) 507 (89.1) 152 (72.4) 443 (94.7)
Subjects With No Missing Data For the Variables Used in the Multiple
Logistic Regression Models
Controls No. 1097 628 330
Percent male 56 41 55
Age at exam, y – mean (sd) 64.3 (8.6) 60.6 (10.2) 60.2 (8.6)
Cases No. 526 193 457
Percent male 52 32 62
Age at diagnosis, y – mean (sd) 60.9 (8.7) 60.5 (10.2) 61.0 (8.9)
Tumor Histological Grade, No. 471 188 402
1 – Well differentiated – No. (%) 49 (10.4) 14 (7.4) 57 (14.2)
2 – Moderately differentiated – No. (%) 363 (77.1) 122 (64.9) 310 (77.1)
3 – Poorly differentiated – No. (%) 59 (12.5) 52 (27.7) 35 (8.7)
Tumor TNM Stage, No. 488 179 Na
Stage I – No. (%) 105 (22.1) 41 (22.9) Na
Stage II – No. (%) 194 (39.8) 59 (33.0) Na
Stage III – No. (%) 161 (33.0) 70 (39.1) Na
Stage IV – No. (%) 28 (5.7) 9 (5.0) Na
Tumor MSI status, No. 526 193 457
MSI high – No. (%) 71 (13.5) 67 (34.7) 40 (8.8)
MSI low – No. (%) 1 (0.2) 41 (21.2) 22 (4.8)
MSI-stable – No. (%) 454 (86.3) 85 (44.0) 395 (86.4)
MLH1 IHC status, No. 526 193 457
IHC present – No. (%) 464 (88.2) 131 (67.9) 423 (92.6)
IHC deficient – No. (%) 62 (11.8) 62 (32.1) 34 (7.4)
SNPs and DNA Methylation
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testing the 74 SNPs in the Ontario samples was equivalent to 28
effective tests; hence, the association P-values were compared to a
critical threshold of P=0.0018, to control the experiment-wise
significance level to 5%. For the Newfoundland data, analysis of
the 19 SNPs constituted 8 effective tests (P-value threshold
=0.0063), and for the Seattle data the 16 SNPs was equivalent to 6
effective tests (P-value threshold =0.0083).
We first tested for association between each SNP and the risk of
CRC (vs. controls), MSI-H CRCs (vs. MSS/L CRCs), MLH1
IHC-deficient CRCs (vs. MLH1 IHC-positive), and with MLH1
promoter methylation (vs. unmethylated MLH1 promoter) (Sup-
plementary File S2). Two SNPs were statistically significantly
associated with increased risk of CRC in Ontario: rs931913
(P=0.001) and rs4624519 (P=0.005).
Three additional SNPs were significantly associated with
increased risk of MSI-H CRCs, MLH1 IHC-deficient CRCs,
and with MLH1 promoter methylated CRCs in Ontario (for
rs1800734 P=0.005, P=0.04, and P=0.018 respectively; for
rs749072 P=3.0610
24, P=0.011, and P=0.003 respectively;
and for rs13098279 P=0.017, P=0.090, and P=0.037 respec-
tively; Supplementary File S2). We examined these findings in
the two other samples: for rs1800734 in Newfoundland,
P=8.53610
25, 1.92610
25, and 8.95610
27 for MSI-H, MLH1
IHC-deficiency, and MLH1 promoter methylation respectively
and, for Seattle, P=0.08, P=0.02, and P=0.04 respectively; for
rs749072 in Newfoundland, P=0.001, P=2.4610
24,
P=6.65610
26 respectively and, for Seattle, P=0.03, P=0.004,
and P=0.014 respectively; for rs13098279 in Newfoundland,
P=4.5610
24, P=4.30610
25, and 1.98610
26 respectively and,
for Seattle, P=0.24, P=0.07, and P=0.14 respectively. See
Supplementary File S2. None of the three latter SNPs were
significantly associated with overall risk of CRC in the three
samples studied (Supplementary File S2). These three SNPs
span a 197.5-kb region with rs1800734 located in the MLH1
promoter, 93 nucleotides upstream of the translational start site;
rs749072 located in intron 26 of LRRFIP2 (IVS26-18T.C); and
rs13098279 located between LRRFIP2 and GOLGA4 (Figure 2).
All three SNPs are in strong linkage disequilibrium in the Ontario
controls (pairwise r
2 .0.73, D’ .0.98). Pairwise D’ and r
2 for all
SNPs genotyped in Ontario control subjects are shown in
Supplementary Figures S1 and S2.
Analysis of all three samples combined revealed strong
associations between rs749072 and decreased risk of MLH1-
promoter-methylated CRC (P=3.80610
26, OR for the common
allele =0.45, CI=0.34–0.60); increased risk of MLH1-protein-
expressing CRC as measured by IHC staining (P=3.99610
27,
OR for the common allele =1.87, CI=1.47–2.39); and decreased
risk of MSI-H CRC (P=2.50610
27, OR for the common allele
=0.55, CI=0.44–0.69). Because the other two SNPs (rs1800734
and rs13098279) are in strong linkage disequilibrium with
rs749072, analyses of these SNPs yielded similar results (Table 2).
In order to examine whether these SNPs were associated with
the pathway that we hypothesized (Figure 1), we next created
logistic regression models for MSI-H versus non-MSI-H CRCs for
the combined dataset (Supplementary File S3). We modelled
MSI-H as a function of each of the upstream predictors, as well as
combinations of predictors: first MLH1 IHC status; then MLH1-
promoter-methylation status; a SNP; both MLH1 IHC status and
MLH1 promoter methylation status; and finally MLH1 IHC
status, MLH1-promoter-methylation status and each SNP
(Table 3). MLH1 IHC status alone was a strong predictor of
MSI-H CRCs (P=2.08610
230) as was the MLH1-promoter-
methylation status (P=1.33610
244) for the SNPs of interest (for
rs1800734, P=2.30610
24, for rs749072 P=1.36610
25, and for
rs13098279 P=5.10610
23). The model with MLH1 IHC status
and MLH1-promoter-methylation status gave the smallest Akaike’s
Information Criterion (AIC) (225.12) and addition of rs13098279
resulted in the second most parsimonious model (AIC=225.94)
(Table 3). In the model with MLH1 IHC status and MLH1-
promoter-methylation status, both variables were statistically
significant, as was the SNP in the model where it was the sole
predictor. However, when the SNP of interest was added to the
model with MLH1 IHC status and MLH1-promoter-methylation
status, the SNP no longer remained statistically significant: the P-
value from the test of significance for rs1800734 changed from
2.30610
24 when it was the sole predictor, to 0.72 when the SNP,
MLH1 promoter methylation status and MLH1 IHC status were
predictors; for rs749072, from 1.36610
25 to 0.98; and for
rs13098279, from 0.005 to 0.29 (Table 3). In the most
parsimonious model, recruitment centre did not have a significant
effect on the model (P $0.26, Supplementary File S3).
We evaluated the same models in the location-specific datasets
and the results were consistent with the combined results
(Supplementary File S3). MLH1 IHC status, MLH1 promoter
methylation status, and the SNPs of interest were all strong
predictors of tumor MSI-H status. The model that included
MLH1 IHC status and MLH1-promoter-methylation status gave
the smallest AIC in all three samples. The addition of any of the
three SNPs did not result in a significantly better model fit
(Supplementary File S3).
Discussion
This large-scale multi-center study examined germline DNA
markers and their contributions to somatic events, especially
susceptibility to DNA methylation in CRC. In three independent
samples, three polymorphisms, rs1800734, rs749072, and
rs13098279 were associated with MLH1-promoter-methylation
status resulting in loss of MLH1 protein and microsatellite
instability. Although these three markers are not associated with
an increase in the risk of CRC overall, they do play a role in
colorectal tumorigenesis in the subset of CRCs that display
genome-wide microsatellite instability. Among cases in each
All Subjects Ontario Seattle Newfoundland
MLH1 promoter methylation status, No. 526 193 457
Methylation positive – No. (%) 54 (10.3) 56 (29.0) 25 (5.5)
Methylation negative – No. (%) 472 (89.7) 137 (71.0) 432 (94.5)
Na = not available, TNM = tumor-node-metastasis, IHC = immunohistochemistry, MSI = microsatellite instability, y = year, sd = standard deviation.
doi:10.1371/journal.pone.0013314.t001
Table 1. Cont.
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combined, statistically significant associations were observed
between each of these three polymorphisms and MLH1 promoter
methylation, MLH1 IHC deficiency, and MSI-H tumor status. In
multiple logistic regression models, each SNP was associated with
tumor MSI-H status; however, once MLH1 IHC deficiency or
MLH1 promoter methylation, or both, were included in the
model, the SNP association was no longer statistically significant.
The observation that the SNP term was not significant in the
model with MLH1 IHC and MLH1 promoter methylation
indicates that the addition of the SNP does not significantly
improve model fit over and above what MLH1 IHC and MLH1
methylation contribute to the model. Hence, MSI status is
conditionally independent of the SNP, or in other words, the
effect of the SNP on MSI status is contained in the effects of
MLH1 IHC and MLH1 methylation on MSI. These results
support the hypothesis that the observed associations between
these polymorphisms and MSI-H status occur through MLH1
methylation and subsequent gene silencing. Furthermore, when
both IHC and methylation status were included in the model,
MLH1 IHC status and MLH1 promoter methylation were both
strongly associated with MSI-H status indicating that these two
events, while highly correlated, are not completely dependent on
each other even after exclusion of all known germline MMR gene
mutation carriers. A similar observation was reported previously
where MLH1 promoter methylation accounted for 80% of MLH1
IHC-deficient-MSI-H CRCs after excluding all MLH1 germline
mutation carriers [27]. Other mechanisms must, then, be
responsible for the remaining 20% of MLH1 IHC-deficient-
MSI-H CRCs. These may include somatic gene mutations,
epimutations, loss of heterozygosity at an MMR gene locus, or
maybe even unidentified microRNA silencing of a MMR gene.
In addition to colon cancer, the MLH1-93G.A polymorphism
(rs1800734) also is associated with other cancers including: ovarian
[28], endometrial [10,29], and secondary tumors arising from
Hodgkin lymphoma [30]. More specifically, the MLH1-93G.A
polymorphism was shown to be associated with MLH1 promoter
methylation in endometrial cancers [10]. Hodgkin lymphoma
patients who carried the variant -93A allele were at higher risk of
developing secondary tumors following methylating chemotherapy
[30]. In the colon, this polymorphism has been shown to increase
the risk of hyperplastic polyps and adenomas in smokers [31] as
well as MSI-H CRCs, alone, or in combination with lifestyle
factors [32]. Furthermore, the MLH1-93G.A polymorphism is
associated with CIMP-positive CRCs (which include MLH1
promoter methylation) [9] and with the loss of MLH1 gene
expression [11], both of which are consistent with the hypothesis
proposed and tested here.
One possible explanation of our previous finding that the
MLH1-93G.A promoter polymorphism was associated with
increased risk of MSI-H CRCs is that the association is caused
by another functional MLH1 polymorphism in strong linkage
disequilibrium (LD) with the MLH1-93G.A SNP [8]. In this
study, we identified two polymorphisms, rs749072 and
rs13098279, that are in strong LD with the MLH1-93G.A
SNP. However, neither of these two polymorphisms are located in
Table 2. Single marker analysis in the combined data for 3 SNPs for CRC cases versus controls, MLH1 promoter methylation, MLH1
IHC staining and MSI tumor status.
Colon Cancer Cases vs. Controls
Marker Common Allele Sample Size P-value OR Lower 95% CI Upper 95% CI
rs1800734 G 3923 0.108 0.915 0.822 1.020
rs749072 T 3912 0.102 0.918 0.828 1.017
rs13098279 G 3912 0.155 0.924 0.828 1.031
MLH1 Promoter Methylation within cases (positive versus negative)
Marker Common Allele Sample Size P-value OR Lower 95% CI Upper 95% CI
rs1800734 G 1236 3.25E-07 0.470 0.352 0.628
rs749072 T 1202 3.80E-06 0.451 0.340 0.599
rs13098279 G 1202 5.80E-06 0.508 0.379 0.681
MLH1 IHC Staining within cases (positive versus negative)
Marker Common Allele Sample Size P-value OR Lower 95% CI Upper 95% CI
rs1800734 G 1674 2.43E-06 1.823 1.420 2.339
rs749072 T 1640 3.99E-07 1.872 1.469 2.386
rs13098279 G 1640 4.71E-05 1.691 1.313 2.179
rs13098279 G 1648 1.15E-04 0.626 0.494 0.794
Tumor MSI Status within cases (MSI-H versus MSS/L)
Marker Common Allele Sample Size P-value OR Lower 95% CI Upper 95% CI
rs1800734 G 1681 3.38E-06 0.574 0.454 0.725
rs749072 T 1648 2.50E-07 0.550 0.439 0.691
Analyses of CRC cases versus controls are adjusted for age, sex, and site.
OR = odds ratio, CI = confidence interval.
Single marker results for the above SNPs for each study population are shown in Supplementary File S2.
doi:10.1371/journal.pone.0013314.t002
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repeat in Flightless interaction protein 2), 18 nucleotides from a
splice acceptor site (IVS26-18T.C); rs13098279 is an intergenic
polymorphism located between the LRRFIP2 and GOLGA4 (golgi
autoantigen, golgin subfamily a, 4). LRRFIP2 binds Dishevelled
and serves as an activator of the Wnt signalling pathway, which is
deregulated in ,85% of CRCs [33]. LRRFIP2 splice variants
were identified in colon and prostate cancers [34]. The spliced
exons contain several potential phosphorylation sites that might
influence protein function [34]. The roles of the identified splice
variants in tumorigenesis, as well as potential effects of rs749072
on splicing machinery, are still unclear.
We identified two additional polymorphisms, rs931913 and
rs4624519, associated with an overall increased risk of CRC in the
Ontario sample. We did not attempt to replicate the findings for
rs931913 and rs4624519 in Newfoundland or Seattle.
Our study has several limitations, including the unavailability of
some clinical data from our study subjects. Clinical and pathologic
characteristics were not available for several reasons (e.g., tumor
material not available for MSI, IHC, or methylation testing,
technical difficulties, or death of the patient before tissue samples
could be obtained). However, because the general clinical and
pathologic characteristics of CRC in our whole population were
similar to those of cases with no missing data, our study was not
limited by this potential source of bias. One exception was the
methylation analysis of Seattle samples, which were mostly
completed on MSI-H cases. However, the results obtained from
the Seattle samples are very similar to those from Ontario and
Newfoundland.
Our study also has numerous strengths. The large sample size
gave us high power and precision. In order to observe statistically
significant associations of the same order of magnitude that we
report here in a genome-wide association study design, we would
require between 23,000 and 61,000 cases and controls. A major
strength of our study is the use of three independent population-
based registries, Ontario, Newfoundland, and Seattle. Replication
of our main findings in two additional independent samples
provides strong evidence that our findings reflect real associations
and are unlikely to have occurred by chance.
The important finding of this study is the identification of a
genetic basis for DNA methylation susceptibility; it indicates that
genetic variants may play an indirect role in increasing the risk of
MSI-H colorectal cancer. Perhaps they alter the binding sites of
transcription factors and DNA-binding proteins that protect the
DNA molecule from methylation. Inability of these protective
proteins to bind DNA would expose DNA to methylating
machinery. Conversely, these polymorphisms may create binding
sites for co-repressors, methylated DNA-binding proteins, or other
proteins involved in epigenetic silencing that modify DNA and
silence gene expression. Another possible mechanism involves the
production of antisense RNA; it was shown recently that increased
production of antisense RNA resulted in epigenetic silencing of
p15 tumor suppressor gene [35]. The polymorphisms in this study
may increase the production of antisense RNAs that result in
epigenetic silencing of the corresponding sense-strand genes.
The fact that polymorphisms in genes other than MLH1 are
associated with DNA methylation may indicate that the MLH1
promoter methylation observed in MSI-H colorectal cancers is not
localized just to the MLH1 locus, but extends beyond the gene.
Indeed, Hitchins et al. observed that, in MSI-H colorectal cancers,
methylation is not limited to the MLH1 promoter region, but
affects genes in a region as large as 2.4 Mega base-pairs [36]. We
may have identified, in a much smaller region, genetic markers of
the predisposition to such epigenetic alterations and, because a
mismatch repair gene, MLH1, is involved, microsatellite instability
invariably develops. However, we cannot yet exclude the
possibility that these markers tag some other unknown variant(s)
that are the true cause of DNA susceptibility to methylation.
The major agent used for the medical treatment of patients with
advanced CRC, 5-Fluorouracil (5-FU), is recognized by the MMR
system [37]. 5-FU selectively kills cells with intact MMR, while
MMR-deficient cells are resistant [37]. Patients with stage II and
III sporadic MSI CRC do not show a survival benefit following 5-
FU therapy when compared with MSS CRC patients in
retrospective and prospective studies [38,39,40]. Indeed, 5-FU-
based adjuvant chemotherapy might decrease overall and disease-
free survival among MSI CRC patients [38]. Similarly, stage III
Lynch Syndrome patients do not show a 5-year survival benefit
with 5-FU treatment over untreated patients [41]. CRC is a
heterogeneous disease and the three polymorphisms used in this
Table 3. Logistic regression model results for MSI status with
various predictor combinations in the combined data.
Model
No. Covariate AIC
Parameter
Estimate
Standard
Error P-value
1 IHC 238.72 7.79 0.68 2.08E-30
2 CH3 470.64 5.56 0.40 1.33E-44
3 IHC 225.12 6.53 0.68 7.36E-22
CH3 3.03 0.66 4.29E-06
4 rs1800734 890.89 20.49 0.13 2.30E-04
5 IHC 240.83 7.74 0.68 2.31E-30
rs1800734 20.03 0.33 0.94
6 CH3 472.63 5.55 0.40 1.52E-43
rs1800734 0.04 0.22 0.85
7 IHC 227.05 6.50 0.67 5.98E-22
CH3 3.06 0.67 5.18E-06
rs1800734 0.12 0.34 0.72
4 rs749072 885.46 20.56 0.13 1.36E-05
5 IHC 240.72 7.72 0.67 2.70E-30
rs749072 20.13 0.31 0.68
6 CH3 472.56 5.52 0.40 2.24E-43
rs749072 20.08 0.21 0.70
7 IHC 227.23 6.48 0.67 5.64E-22
CH3 3.01 0.66 5.72E-06
rs749072 20.01 0.32 0.98
4 rs13098279 896.57 20.38 0.14 0.0051
5 IHC 240.41 7.80 0.68 2.73E-30
rs13098279 0.21 0.35 0.55
6 CH3 471.93 5.60 0.40 1.23E-43
rs13098279 0.19 0.23 0.41
7 IHC 225.94 6.55 0.68 1.04E-21
CH3 3.17 0.69 3.74E-06
rs13098279 0.39 0.37 0.29
Age at diagnosis, sex, and location are covariates common to all the models
described above. IHC refers to the MLH1 immunohistochemical staining
variable, CH3 refers to the MLH1 promoter methylation variable, AIC = Akaike’s
information criterion. Logistic regression models for each SNP per study
population and for the combined data are shown in Supplementary File S3.
The role of three SNPs of interest, rs1800734, rs749072, and rs13098279, is
explored.
doi:10.1371/journal.pone.0013314.t003
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early identification of MSI and selection of optimal therapies.
In summary, we built on our previous finding, an association of
the MLH1-93G.A polymorphism with MSI-H colorectal cancers
[8]. We identified a novel mechanism in which common missense
alterations may contribute to complex disease. The three
polymorphisms reported in this study serve as germline mar-
kers/predisposition alleles for a somatic event that will result in
gene silencing and consequently, a specific subtype of colorectal
cancer. Additional characterization of these the genes and
polymorphisms noted here may lead to new insights and new
mechanisms by which alleles contribute to cancer incidence and
progression.
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